CG Oncology (CGON) Interest & Investment Income (2023 - 2026)
CG Oncology (CGON) posted Interest & Investment Income of $6.3 million for Q1 2026, down 15.53% on a QoQ basis from $7.4 million in Q4 2025, and down 18.83% year-over-year from $7.7 million in Q1 2025.
CG Oncology (CGON) Interest & Investment Income (2023 - 2026) Analysis & Trends
CG Oncology's Interest & Investment Income history runs 4 years deep, the most recent figure standing at $6.3 million for Q1 2026.
- Quarterly Interest & Investment Income fell 18.83% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.5 million (down 1.23% YoY) and the FY2025 annual result came in at $29.9 million, up 12.42% from the prior year.
- Interest & Investment Income was $6.3 million for Q1 2026 at CG Oncology, down from $7.4 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $7.9 million in Q3 2024 and bottomed at $771000.0 in Q2 2023.
- A 4-year average of $5.4 million and a median of $6.3 million in 2026 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income jumped 800.52% — and 2026, when it declined 18.83%.
- CG Oncology's Interest & Investment Income stood at $2.8 million in 2023, then soared by 122.72% to $6.2 million in 2024, then increased by 19.2% to $7.4 million in 2025, then retreated by 15.53% to $6.3 million in 2026.
- Business Quant data shows CGON's Interest & Investment Income at $6.3 million in Q1 2026, $7.4 million in Q4 2025, and $7.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | CG Oncology | 5.86 Bn | 5.86 Bn | -1.88 Mn | 6.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.29 Mn |
| Dec 31, 2025 | 7.44 Mn |
| Sep 30, 2025 | 7.42 Mn |
| Jun 30, 2025 | 7.32 Mn |
| Mar 31, 2025 | 7.75 Mn |
| Dec 31, 2024 | 6.25 Mn |
| Sep 30, 2024 | 7.89 Mn |
| Jun 30, 2024 | 6.94 Mn |
| Mar 31, 2024 | 5.54 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 2.28 Mn |
| Jun 30, 2023 | 771,000.00 |
| Mar 31, 2023 | 1.05 Mn |